Junctional Adhesion Molecule 2 (JAM2) Antibody
234€ (5 µg)
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
935106861
info@markelab.com
name
Junctional Adhesion Molecule 2 (JAM2) Antibody
category
Primary Antibodies
provider
Abbexa
reference
abx137631
Description
Junctional Adhesion Molecule 2 (JAM2) Antibody is a Mouse Monoclonal antibody against Junctional Adhesion Molecule 2 (JAM2).
Documents del producto
Instrucciones
Data sheet
Product specifications
| Category | Primary Antibodies |
| Immunogen Target | Junctional Adhesion Molecule 2 (JAM2) |
| Host | Mouse |
| Reactivity | Human |
| Clonality | Monoclonal |
| Size 1 | 5 µg |
| Size 2 | 20 µg |
| Size 3 | 100 µg |
| Availability | Shipped within 5-10 working days. |
| Dry Ice | No |
| Alias | JAMB,CD322,IBGC8,JAM-B,VEJAM,PRO245,VE-JAM,C21orf43,Vascular endothelial junction-associated molecule,Junctional adhesion molecule B |
| Background | Antibody anti-JAM2 |
| Status | RUO |
Descripción
JAM2 is a member of the Junctional Adhesion Molecule (JAM) family, part of the immunoglobulin superfamily, and is primarily expressed in endothelial cells, lymphatic vessels, and certain immune cells. Structurally, JAM2 consists of two extracellular Ig-like domains, a single transmembrane domain, and a short cytoplasmic tail that interacts with intracellular signaling molecules and the actin cytoskeleton. JAM2 is involved in cell-cell adhesion, particularly in maintaining endothelial barrier integrity and regulating the movement of immune cells through endothelial junctions. It plays a role in leukocyte transmigration during inflammation and immune surveillance by interacting with integrins, including α4β1 integrin on leukocytes. JAM2 also mediates vascular permeability and contributes to the organization of tight junctions between endothelial and epithelial cells. JAM2 is implicated in pathological processes such as inflammatory diseases, autoimmunity, and cancer metastasis, where it regulates the extravasation of leukocytes and cancer cells. Dysregulation of JAM2 has been linked to abnormal vascular permeability and inflammatory responses, making it a potential therapeutic target in conditions like vascular inflammation and tumor progression.
Related Products
anti- JAM2 antibody
May play a role in the processes of lymphocyte homing to secondary lymphoid organs.
Ver Producto
Recombinant Human JAM-B
Ver Producto